Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.060
+0.120 (3.05%)
Apr 1, 2026, 9:44 AM EDT - Market open
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$993,219
Profits / Employee
-$2,653,263
Market Cap
95.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Sep 30, 2022 | 6 | 0 | - |
| Jun 30, 2022 | 6 | - | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Fortress Biotech | 101 |
| Seres Therapeutics | 66 |
| Pyxis Oncology | 44 |
| Biomea Fusion | 42 |
| Vivani Medical | 37 |
| Oncolytics Biotech | 28 |
| LeonaBio | 26 |
COYA News
- 14 days ago - Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
- 16 days ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - Business Wire
- 7 weeks ago - Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Business Wire
- 2 months ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 2 months ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 2 months ago - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
- 3 months ago - Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - Business Wire
- 3 months ago - Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire